Efficacy
SECONDARY, DISEASE
The proportion of patients showing an improvement in ESSDAI score at week 12 was not significantly different between the RO5459072 and placebo arms (42.1% Primary and secondary efficacy outcomes at week 12Baseline is the patient’s last observation prior to initiation of study drug.Patients with ≥3 point reduction from baseline in ESSDAI at week 12 were classified as responders.Patients with ≥1 point reduction from baseline in ESSPRI at week 12 were classified as responders. Patients with a missing response were classed as non-responders. ESSDAI: EULAR SS Disease Activity Index; ESSPRI: EULAR SS Patient Reported Index; SF-36: Short Form-36 Health Survey.There were no statistically significant differences between the RO5459072 and placebo arms for the secondary clinical endpoints (There was no significant difference between the placebo and RO5459072 groups in the proportion of ESSPRI responders (defined as patients with ≥1 point reduction from baseline in ESSPRI score at week 12; The findings for unstimulated tear production and mechanically stimulated salivary flow likewise showed no significant differences. Although the RO5459072 group showed a smaller decline compared with the placebo group at week 12 for unstimulated tear production, these differences were not statistically significant (